Video
Dr. Stone Discusses Monitoring MRD in AML
Author(s):
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML).
One of the most important questions in AML is the clinical relevance of monitoring MRD, says Stone.
Historically, AML therapy success has been measured based on morphologic assessment of the bone marrow. If there are less than 5% blasts in the marrow, the patient is deemed to be in remission—but researchers now want a way to measure the depth of that remission.
